GSK Takes A Header As Vaccine Sales Plummet, Miss

By Investor's Business Daily | Oct 30, 2024 at 09:02 AM EST

GSK stock plummeted due to declining vaccine sales in Q3. Sales dropped 2% to 8.01 billion pounds, missing analyst estimates. Vaccine sales, notably for Arexvy and Shingrix, fell, but GSK maintains its sales growth outlook for the year.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.